338 related articles for article (PubMed ID: 15540755)
1. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.
Cardozo L; Lisec M; Millard R; van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang M; Ridder AM
J Urol; 2004 Nov; 172(5 Pt 1):1919-24. PubMed ID: 15540755
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.
Choo MS; Lee JZ; Lee JB; Kim YH; Jung HC; Lee KS; Kim JC; Seo JT; Paick JS; Kim HJ; Na YG; Lee JG
Int J Clin Pract; 2008 Nov; 62(11):1675-83. PubMed ID: 19143854
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder.
Chu F; Smith N; Uchida T
Curr Ther Res Clin Exp; 2009 Dec; 70(6):405-20. PubMed ID: 24692834
[TBL] [Abstract][Full Text] [Related]
8. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.
Brunton S; Kuritzky L
Curr Med Res Opin; 2005 Jan; 21(1):71-80. PubMed ID: 15881477
[TBL] [Abstract][Full Text] [Related]
10. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
Chapple CR; Araño P; Bosch JL; De Ridder D; Kramer AE; Ridder AM
BJU Int; 2004 Jan; 93(1):71-7. PubMed ID: 14678372
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of solifenacin in patients with overactive bladder syndrome.
Oresković S; But I; Banović M; Goldstajn MS
Coll Antropol; 2012 Mar; 36(1):243-8. PubMed ID: 22816227
[TBL] [Abstract][Full Text] [Related]
12. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
14. Solifenacin significantly improves all symptoms of overactive bladder syndrome.
Chapple CR; Cardozo L; Steers WD; Govier FE
Int J Clin Pract; 2006 Aug; 60(8):959-66. PubMed ID: 16893438
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
Millard RJ; Halaska M
Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429
[TBL] [Abstract][Full Text] [Related]
16. Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial.
Newgreen D; Bosman B; Hollestein-Havelaar A; Dahler E; Besuyen R; Sawyer W; Bolduc S; Rittig S
Eur Urol; 2017 Mar; 71(3):483-490. PubMed ID: 27687820
[TBL] [Abstract][Full Text] [Related]
17. Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.
Abrams P; Swift S
Eur Urol; 2005 Sep; 48(3):483-7. PubMed ID: 16005564
[TBL] [Abstract][Full Text] [Related]
18. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study.
Mattiasson A; Masala A; Morton R; Bolodeoku J;
BJU Int; 2010 Apr; 105(8):1126-35. PubMed ID: 19818077
[TBL] [Abstract][Full Text] [Related]
20. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
